Saxena, M., van der, Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic most cancers vaccines. Nat. Rev. Most cancers 21, 360–378 (2021).
Zhang, L. et al. Nanovaccine’s fast induction of anti-tumor immunity considerably improves malignant most cancers immunotherapy. Nano As we speak 35, 100923 (2020).
Gardner, A. & Ruffell, B. Dendritic cells and most cancers immunity. Tendencies Immunol. 37, 855–865 (2016).
Yang, W., Zhou, Z., Lau, J., Hu, S. & Chen, X. Purposeful T cell activation by sensible nanosystems for efficient most cancers immunotherapy. Nano As we speak 27, 28–47 (2019).
Lee, D. Y., Huntoon, Ok., Wang, Y., Jiang, W. & Kim, B. Y. S. Harnessing innate immunity utilizing biomaterials for most cancers immunotherapy. Adv. Mater. 33, 2007576 (2021).
Liang, J. & Zhao, X. Nanomaterial-based supply automobiles for therapeutic most cancers vaccine growth. Most cancers Biol. Med. 18, 352–371 (2021).
Liu, G., Zhu, M., Zhao, X. & Nie, G. Nanotechnology-empowered vaccine supply for enhancing CD8+ T cells-mediated mobile immunity. Adv. Drug. Deliv. Rev. 176, 113889 (2021).
Cabral, M. G. The phagocytic capability and immunological efficiency of human dendritic cells is improved by α2,6-sialic acid deficiency. Immunology 138, 235–245 (2013).
Zhu, N. et al. Comparability of immunoregulatory results of polysaccharides from three pure herbs and mobile uptake in dendritic cells. Int. J. Biol. Macromol. 93, 940–951 (2016).
Patin, E. Pure variation within the parameters of innate immune cells is preferentially pushed by genetic components. Nat. Immunol. 19, 302–314 (2018).
Dominguez-Andres, J. & Netea, M. G. Lengthy-term reprogramming of the innate immune system. J. Leukoc. Biol. 105, 329–338 (2019).
Netea, M. G., Quintin, J. & van der Meer, J. W. Educated immunity: a reminiscence for innate host protection. Cell Host Microbe 9, 355–361 (2011).
Netea, M. G., Schlitzer, A., Placek, Ok., Joosten, L. A. B. & Schultze, J. L. Innate and adaptive immune reminiscence: an evolutionary continuum within the host’s response to pathogens. Cell Host Microbe 25, 13–26 (2019).
Netea, M. G. et al. Defining skilled immunity and its position in well being and illness. Nat. Rev. Immunol. 20, 375–388 (2020).
Netea, M. G. et al. Educated immunity: a program of innate immune reminiscence in well being and illness. Science 352, aaf1098 (2016).
Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protecting innate immunity towards tuberculosis. Cell 172, 176–190.e19 (2018).
Mitroulis, I. et al. Modulation of myelopoiesis progenitors is an integral element of skilled immunity. Cell 172, 147–161.e12 (2018).
Jentho, E. et al. Educated innate immunity, long-lasting epigenetic modulation, and skewed myelopoiesis by heme. Proc. Natl Acad. Sci. USA 118, e2102698118 (2021).
Bekkering, S., Dominguez-Andres, J., Joosten, L. A. B., Riksen, N. P. & Netea, M. G. Educated immunity: reprogramming innate immunity in well being and illness. Annu. Rev. Immunol. 39, 667–693 (2021).
Kleinnijenhuis, J. et al. Lengthy-lasting results of BCG vaccination on each heterologous Th1/Th17 responses and innate skilled immunity. J. Innate. Immunol. 6, 152–158 (2014).
Novakovic, B. et al. β-glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368.e14 (2016).
Cirovic, B. et al. BCG vaccination in people elicits skilled immunity through the hematopoietic progenitor compartment. Cell Host Microbe 28, 322–334.e5 (2020).
Christ, A. et al. Western weight loss plan triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162–175.e14 (2018).
Crisan, T. O. et al. Uric acid priming in human monocytes is pushed by the AKT-PRAS40 autophagy pathway. Proc. Natl Acad. Sci. USA 114, 5485–5490 (2017).
Teufel, L. U., Arts, R. J. W., Netea, M. G., Dinarello, C. A. & Joosten, L. A. B. IL-1 household cytokines as drivers and inhibitors of skilled immunity. Cytokine 150, 155773 (2022).
Moorlag, S. J. C. F. M., Roring, R. J., Joosten, L. A. B. & Netea, M. G. The position of the interleukin-1 household in skilled immunity. Immunol. Rev. 281, 28–39 (2018).
Swanson, Ok. V., Deng, M. & Ting, J. PY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and kind III secretion equipment. Nature 477, 596–600 (2011).
Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).
Priem, B. et al. Educated immunity-promoting nanobiologic remedy suppresses tumor development and potentiates checkpoint inhibition. Cell 183, 786–801.e19 (2020).
Schwechheimer, C. & Kuehn, M. J. Outer-membrane vesicles from Gram-negative micro organism: biogenesis and capabilities. Nat. Rev. Microbiol. 13, 605–619 (2015).
Li, M. et al. Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity. Nano As we speak 35, 101007 (2020).
Yue, Y. et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered micro organism. Nat. Biomed. Eng. 6, 898–909 (2022).
Li, Y. et al. Speedy floor show of mRNA antigens by bacteria-derived outer membrane vesicles for a personalised tumor vaccine. Adv. Mater. 34, e2109984 (2022).
Cheng, Ok. et al. Bioengineered bacteria-derived outer membrane vesicles as a flexible antigen show platform for tumor vaccination through plug-and-display expertise. Nat. Commun. 12, 2041 (2021).
Liang, J. et al. Customized most cancers vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells. Basic Res. 2, 23–36 (2022).
Rathinam, V. A. Ok., Zhao, Y. & Shao, F. Innate immunity to intracellular LPS. Nat. Immunol. 20, 527–533 (2019).
Vanaja, S. Ok. et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell 165, 1106–1119 (2016).
Youngblood, B. et al. Effector CD8 T cells dedifferentiate into long-lived reminiscence cells. Nature 552, 404–409 (2017).
Thompson, J. C. et al. Gene signature of antigen processing and presentation equipment predicts response to checkpoint blockade in non-small cell lung most cancers (NSCLC) and melanoma. J. Immunother. Most cancers 8, e000974 (2020).
Kelly, A. & Trowsdale, J. Genetics of antigen processing and presentation. Immunogenetics 71, 161–170 (2019).
Mangold, C. A. et al. CNS-wide sexually dimorphic induction of the key histocompatibility complicated 1 pathway with ageing. J. Gerontol. A. Biol. Sci. Med. Sci. 72, 16–29 (2017).
Vasu, C. et al. CD80 and CD86 C domains play an vital position in receptor binding and co-stimulatory properties. Int. Immunol. 15, 167–175 (2003).
Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, irritation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).
Xu, B. et al. CCR9 and CCL25: a evaluation of their roles in tumor promotion. J. Cell. Physiol. 235, 9121–9132 (2020).
Fischer, A. et al. ZAP70: a grasp regulator of adaptive immunity. Semin. Immunopathol. 32, 107–116 (2010).
Lin, Q. et al. Epigenetic program and transcription issue circuitry of dendritic cell growth. Nucleic Acids Res. 43, 9680–9693 (2015).
Karrich, J. J. et al. The transcription issue Spi-B regulates human plasmacytoid dendritic cell survival via direct induction of the antiapoptotic gene BCL2-A1. Blood 119, 5191–5200 (2012).
Schotte, R., Nagasawa, M., Weijer, Ok., Spits, H. & Blom, B. The ETS transcription issue Spi-B is required for human plasmacytoid dendritic cell growth. J. Exp. Med. 200, 1503–1509 (2004).
Kanada, S. et al. Crucial position of transcription issue PU.1 within the expression of CD80 and CD86 on dendritic cells. Blood 117, 2211–2222 (2011).
Cheng, S. et al. mTOR- and HIF-1α-mediated cardio glycolysis as metabolic foundation for skilled immunity. Science 345, 1250684 (2014).
Dinarello, C. A. Overview of the IL-1 household in innate irritation and purchased immunity. Immunol. Rev. 281, 8–27 (2018).
Gillard, J. et al. BCG-induced skilled immunity enhances acellular pertussis vaccination responses in an explorative randomized medical trial. NPJ Vaccines 7, 21 (2022).
Acevedo, R. et al. Bacterial outer membrane vesicles and vaccine functions. Entrance. Immunol. 5, 121 (2014).
